|
|
|
Saturday, March 17, 2012 — 7:00 p.m. — Convention Centre 220-222
|
- Diagnosing Lung Carcinoma in the Era of Personalized Medicine: Clinical, Pathologic, and Molecular Aspects
|
|
Moderator:
|
Matthew A. Zarka, Mayo Clinic Arizona, Scottsdale, AZ
|
Click the button above to add this event to your Itinerary Planner...
| 7:00 |
Introduction - Matthew A. Zarka, Mayo Clinic Arizona, Scottsdale, AZ |
| 7:15 |
Clinical Approach to Cytologic and Histologic Sampling in the Patient with Lung Cancer - Robert Viggiano, Mayo Clinic Arizona, Scottsdale, AZ |
| 7:50 |
Practical Approach to the Diagnosis and Management of Nonsmall Cell Lung Cancer Encountered in Limited Biopsy Samples (Transbronchial and Needle Core) - Kevin O. Leslie, Mayo Clinic Arizona, Scottsdale, AZ |
| 8:25 |
AMP—CAP—IASLC Guidelines for Molecular Testing of Lung Adenocarcinoma - Neal Lindeman, Harvard Medical School, Boston, MA |
| 9:00 |
Respiratory Tract Cytology: From Basic Morphology to Advanced Molecular Analysis - Kim R. Geisinger, Wake Forest Baptist Medical Center, Winston-Salem, NC |
| 9:35 | Question and Answer Session |
The PSC and ASC solicited topics of interest from their membership at the annual business meetings. Several potential topics were discussed at the Executive Board meeting and the topic for the 2012 session was chosen in agreement with the chairs of the scientific program committees.
Keeping abreast of the advantages and limitations of transbronchial biopsy and endobronchial ultrasound biopsy (EBUS) and subclassification of lung tumors based upon small tissue fragments and cytology is of high interest to the members of the PSC, particularly in a time when there have been recent advances in the categorization of lung tumors based upon new immunohistologic and molecular techniques. This new knowledge regarding the tumor biology of non-small lung cancers has prompted a new proposal to classify adenocarcinomas of the lung based upon the recent IASLC 2011 consensus publication. Choice of specific targeted therapies to lung cancers is dependent upon accurate subclassification of lung carcinomas.
Our needs assessment process was based on the evaluation of the current literature and the feedback provided by audience participating in our prior companion society sessions.
The purpose and objectives of the program are as follows: 1) Provide a pathologists view of the clinical role of transbronchial biopsy and endobronchial ultrasound biopsy (EBUS) in the diagnosis and staging of lung carcinoma. 2) Highlight the practical approach of lung carcinoma with limited cytologic and histologic biopsy material. 3) Understand the sensitivity and specificity of the various cytologic techniques involved in the diagnosis of lung cancer, and the essential cytologic and histologic criteria required for the subclassification of lung tumors, including adenocarcinomas, based upon the new proposed IASLC 2011 consensus publication. 4) Describe the role of the molecular techniques in the diagnosis and prediction of response to therapy of lung adenocarcinoma based on small biopsy specimens.
Evaluations through the USCAP are required in order to obtain CME credit. We also will evaluate effectiveness by monitoring attendance and tracking the scope and breadth of questions and the evaluations of each speaker.
|
|
|
|
